BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Genomic Health, Inc. 

301 Penobscot Drive

Redwood City  California  94063  U.S.A.
Phone: 650-556-9300 Fax: 650-556-1132


Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 70 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. Based in Redwood City, Calif. with European headquarters in Geneva, Switzerland, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey.

 Key Statistics

Ownership: Public

Web Site: Genomic Health, Inc.
Symbol: GHDX


 Company News
Genomic Health, Inc. (GHDX) Announces Favorable Draft Local Coverage Determination From Palmetto GBA On Medicare Coverage For The Oncotype DX Prostate Cancer Test 5/21/2015 6:49:48 AM
Genomic Health, Inc. (GHDX) Advances Liquid Biopsy Pipeline, Shows Ability To Accurately Monitor Urine For Presence Of Bladder Cancer 5/18/2015 6:53:56 AM
Genomic Health, Inc. (GHDX) Release: Oncotype DX Prostate Cancer Test Improves Risk Assessment For One In Four Men And Reduces Overall Healthcare Costs 5/15/2015 6:43:43 AM
Genomic Health, Inc. (GHDX) To Present Multiple Oncotype DX Studies And Positive Liquid Biopsy Results At American Urological Association Annual Meeting May 15-19 5/7/2015 12:20:37 PM
Genomic Health, Inc. (GHDX) To Present At The Bank of America (BAC) Merrill Lynch 2015 Healthcare Conference 5/6/2015 11:19:54 AM
Genomic Health, Inc. (GHDX) Announces First Quarter 2015 Financial Results And Reports Record Oncotype DX Test Volume 5/6/2015 7:57:48 AM
Genomic Health, Inc. (GHDX) Announces Publication of Oncotype DX Prostate Cancer Test Decision Impact Study In Urology Practice, Supporting Wider Adoption And Reimbursement 4/30/2015 6:23:03 AM
Genomic Health, Inc. (GHDX) To Announce First Quarter 2015 Financial Results And Host Conference Call On Tuesday, May 5, 2015 4/28/2015 10:56:53 AM
Genomic Health, Inc. (GHDX) Release: Multiple Data Presentations Demonstrate Positive Direct Patient Impact Of Oncotype DX Breast Cancer Test Globally 3/20/2015 7:06:52 AM
Genomic Health, Inc. (GHDX) Announces Year-End 2014 Financial Results, Provides 2015 Financial Outlook 2/11/2015 10:32:18 AM